Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

se technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effectively target and inhibit production of specific proteins in tumor cells. OncoGenex and Isis partnered in the successful discovery of OGX-011, OGX-427 and OGX-225 and with respect to OGX-011, in its initial development. In 2008, OncoGenex and Isis amended their OGX-011 agreement to provide OncoGenex with sole rights to OGX-011 and sole responsibility for development and related costs and partnering decisions, subject to financial obligations to Isis. OncoGenex is also solely responsible for development and related costs and partnering decisions regarding OGX-427 and OGX-225. Key intellectual property related to OGX-011, OGX-427 and OGX-225 were discovered by the University of British Columbia and the Vancouver Prostate Centre, and were exclusively licensed to OncoGenex.

More information about OncoGenex is available at www.oncogenex.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements concerning the potential survival benefit of OGX-011, anticipated clinical development activities, timing of these activities, the ability of future trials to demonstrate clinical benefit and the potential for regulatory approvals. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS) ... the three months ended March 31, 2015 and provided ... in Canadian dollars. Effective July 17, ... May 31 to December 31. As a result of ... for the three months ended March 31, 2015, while ...
(Date:5/5/2015)... , May 05, 2015 Research ... has announced the addition of the ... to their offering. Macromolecules which ... undergo separation or are broken into smaller ... products. This separation requires various advanced systems ...
(Date:5/5/2015)... 2015 Reprints Desk, Inc., a Research Solutions ... to scientific, technical and medical (STM) content, today announced ... of Southeastern Research Libraries (ASERL) . ASERL ... 11 southeastern states. Founded in 1956, ASERL has a ... address the continually changing needs of its member libraries. ...
(Date:5/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/x5gjj3/clinical ) ... Laboratory, Molecular Diagnostics and Genomic Testing Services Market ... Version" report to their offering. ... molecular diagnostics and pharmacogenics hold the promise of ... is moving out of the national and regional ...
Breaking Biology Technology:Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 2Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 3Association of Southeastern Research Libraries Partners with Reprints Desk to Improve Access for Hard-to-Find Materials 4Global Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market Trends and Forecast 2015 to 2019 2
... medical equipment specialists at Medical Machines Online are announcing the release and ... AED Defibrillator. , ... San Diego, CA (PRWEB) December 31, 2008 -- ... new Philips HeartStart AED Defibrillator. This system is one of many pieces ...
... 31 The United States Food & Drug,Administration (FDA) today ... blood for HIV-1 Group M RNA, hepatitis C RNA and ... the cobas TaqScreen MPX,Test for use on the cobas s ... detection of HIV-1 Group M RNA, HIV-1 Group O RNA,HIV-2 ...
... Listed While it , Engages in Compliance ProcessCRANBURY, ... US: PTN) today reported it received notice from NYSE ... American Stock Exchange), advising Palatin that it is not ... listing standards under Section 1003 of the Exchange,s Company ...
Cached Biology Technology:Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 2Medical Machines Online Announces Release of a Brand New Philips HeartStart AED Defibrillator 3FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C 2FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C 3Palatin Technologies Receives Notification Letter from NYSE Alternext US 2Palatin Technologies Receives Notification Letter from NYSE Alternext US 3
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
(Date:3/26/2015)... , March 26, 2015 The ... social, recreation and athletic club, today announced it has ... allow freedom of movement for members and staff, while ... a comprehensive process, we selected FST,s IMID Access system ... convenience for our members and staff, in addition to ...
(Date:3/24/2015)... --  NexID Biometrics LLC, whose spoof-mitigation technology boosts ... the beginning of shipments of version 2.0 of its ... based in Potsdam, N.Y. , is ... began here today at the Walter E. Washington Convention ... SDK boosts the accuracy rate range to 96.5 to ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... sea levels, new research indicates that cutting emissions of ... this century. The research team found that reductions ... atmosphere could temporarily forestall the rate of sea level ... avoid potentially dangerous sea level rise, we could cut ...
... bacteria use to defend themselves against viruses, has been found ... immune system. The results are scheduled for publication Sunday, ... a sort of immune system for bacteria. Its function was ... viruses that infect bacteria, from ruining the cultures used to ...
... Reserve School of Medicine have discovered a technique that ... cells destroyed in patients with multiple sclerosis, cerebral palsy ... discovery appears today in the journal Nature Biotechnology ... of myelinating cells, which provide a vital sheath of ...
Cached Biology News:Cutting specific pollutants would slow sea level rise 2Cutting specific pollutants would slow sea level rise 3Bacterial security agents go rogue 2Bacterial security agents go rogue 3Ordinary skin cells morphed into functional brain cells 2
... Restriction Grade Thrombin is a highly purified ... produced with appropriate vectors. The preparation is ... and is free of detectable contaminating proteases. ... shown by certified tests to be negative ...
Rat Cardiac Fibroblasts (RCF) (>500,000 cells)...
...
Rat Aortic Smooth Muscle Cells (RAOSMC) (>500,000 cells)...
Biology Products: